<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035345</url>
  </required_header>
  <id_info>
    <org_study_id>13-413</org_study_id>
    <nct_id>NCT02035345</nct_id>
  </id_info>
  <brief_title>Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment</brief_title>
  <official_title>Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine if administering carboplatin at a slower rate when
      re-treating recurrent ovarian cancer patients prior to the development of a hypersensitivity
      reaction will decrease the frequency and severity of future hypersensitivity reactions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For women with recurrent ovarian cancer, re-treatment with carboplatin is frequently
      recommended. However, carboplatin re-treatment can result in an allergic or allergic-like
      reaction called a hypersensitivity reaction. Symptoms of a hypersensitivity reaction can
      include, but are not limited to itching, rash, swelling of the lips, tongue, or throat, chest
      pain, chest tightness, shortness of breath, wheezing, abdominal pain, nausea, vomiting,
      diarrhea, palpitations, dizziness, confusion, and low pressure. Hypersensitivity reactions
      occur in 20-40% of women with recurrent ovarian cancer who are re-treated with carboplatin.
      At least half of the hypersensitivity reactions are described as moderately severe with
      symptoms of generalized rash, wheezing, facial swelling, difficulty breathing/shortness of
      breath, and hypotension (low blood pressure).

      Patients who suffer from a hypersensitivity reaction while receiving carboplatin and require
      additional therapy may receive future carboplatin infusions utilizing a &quot;desensitization&quot;
      technique. A desensitization is when carboplatin is administered in slowly increasing amounts
      as an inpatient under the direction of the department of Allergy Immunology at Massachusetts
      General Hospital. A desensitization allows patient to safely receive carboplatin, but
      requires an inpatient hospitalization, which may be of significant inconvenience to some
      patients.

      As part of this study, the participant will continue to receive carboplatin as part of their
      standard therapy. The change would be instead of carboplatin being administered over a 30
      minute period, the carboplatin be administered intravenously according to the following
      schedule:

        -  First hour - Administer 1 percent of total dose

        -  Second hour - Administer 9 percent

        -  Third hour - Administer 90 percent

      Standard pre-medications will be administered immediately prior to the carboplatin infusion
      which will include of 20 mg of dexamethasone, 50mg of diphenhydramine, and famotidine 20 mg.

      The participant's medical record will also be reviewed to evaluate whether age, cancer
      stage/grade, number of previous carboplatin cycles, accompanying agents, and/or medical
      conditions have an effect on hypersensitivity reactions. The participant will also be asked
      to fill out a short optional form regarding race and ethnicity to evaluate whether or not
      these factors contribute to hypersensitivity reactions.

      If the participant experiences a hypersensitivity reaction, the study protocol will be
      discontinued. A standard blood draw for a tryptase (a blood test for an allergic reaction)
      will be obtained at the time of the reaction along with other discretionary laboratories
      recommended by your oncologist. The participant will then be referred to the Allergy
      Immunology Department if carboplatin is determined to be necessary for future treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Carboplatin Infusion Hypersensitivity Reactions Using a Slowed Carboplatin Infusion Program</measure>
    <time_frame>2 Years</time_frame>
    <description>To determine the frequency of carboplatin infusion hypersensitivity reactions using a slowed carboplatin infusion program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Carboplatin Reactions of Different Severity</measure>
    <time_frame>2 Years</time_frame>
    <description>To characterize the nature and symptoms of carboplatin reactions associated with the slowed infusion protocol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <condition>Platinum Sensitive Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
First hour - Administer 1 percent of total dose (5ml with tubing primed)
Second hour - Administer 9 percent (45 mL)
Third hour - Administer 90 percent (450 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Carboplatin</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>CBDCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically or cytologically confirmed ovarian cancers for
             which carboplatin is an acceptable treatment option. In addition, participants must be
             candidates for systemic chemotherapy as determined by their treating physician.

          -  Participants must have received a carboplatin-containing regimen at initial diagnosis.
             Retreatment is permitted in second or greater line with carboplatin-based
             chemotherapy.

          -  Age â‰¥ 18 years of age

          -  Eastern Cooperative Oncology Group performance status &lt;2 (see Appendix A).

          -  Women of childbearing potential must have a negative serum pregnancy test within 72
             hours prior to initiating chemotherapy on trial and must agree to practice an
             effective method of birth control, such as an intrauterine device, tubal ligation, or
             oral contraceptives, during the study and for six months after their last treatment.
             Women should not breast-feed while on this study

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients must be willing to comply with study design and requirements for
             participating on the study.

          -  Laboratory Criteria for eligibility The following are laboratory criteria for baseline
             absolute neutrophil count, platelet count, and creatinine for inclusion on this study.

        Exclusion Criteria:

          -  Participants who exhibit any of the following conditions at screening will not be
             eligible for admission into the study.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to carboplatin.

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleena Banerji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <results_first_submitted>August 30, 2016</results_first_submitted>
  <results_first_submitted_qc>October 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2016</results_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Aleena Banerji</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Recurrent Ovarian Cancer</keyword>
  <keyword>Platinum Sensitive Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboplatin</title>
          <description>Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
First hour - Administer 1 percent of total dose (5ml with tubing primed)
Second hour - Administer 9 percent (45 mL)
Third hour - Administer 90 percent (450 mL)
Carboplatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboplatin</title>
          <description>Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
First hour - Administer 1 percent of total dose (5ml with tubing primed)
Second hour - Administer 9 percent (45 mL)
Third hour - Administer 90 percent (450 mL)
Carboplatin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Carboplatin Infusion Hypersensitivity Reactions Using a Slowed Carboplatin Infusion Program</title>
        <description>To determine the frequency of carboplatin infusion hypersensitivity reactions using a slowed carboplatin infusion program</description>
        <time_frame>2 Years</time_frame>
        <population>Total number of patients in the study that received carboplatin via slowed infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplain Slowed Infusion Group Reactors</title>
            <description>Patients that received carboplatin via slowed infusion that developed a reaction</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Carboplatin Infusion Hypersensitivity Reactions Using a Slowed Carboplatin Infusion Program</title>
          <description>To determine the frequency of carboplatin infusion hypersensitivity reactions using a slowed carboplatin infusion program</description>
          <population>Total number of patients in the study that received carboplatin via slowed infusion.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Carboplatin Reactions of Different Severity</title>
        <description>To characterize the nature and symptoms of carboplatin reactions associated with the slowed infusion protocol.</description>
        <time_frame>2 Years</time_frame>
        <population>Among the 15 patients enrolled, the HSR rate was 40% which occurred after a median of 2 protocol treatments, which prompted early termination of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin</title>
            <description>Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
First hour - Administer 1 percent of total dose (5ml with tubing primed)
Second hour - Administer 9 percent (45 mL)
Third hour - Administer 90 percent (450 mL)
Carboplatin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Carboplatin Reactions of Different Severity</title>
          <description>To characterize the nature and symptoms of carboplatin reactions associated with the slowed infusion protocol.</description>
          <population>Among the 15 patients enrolled, the HSR rate was 40% which occurred after a median of 2 protocol treatments, which prompted early termination of this study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Carboplatin</title>
          <description>Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
First hour - Administer 1 percent of total dose (5ml with tubing primed)
Second hour - Administer 9 percent (45 mL)
Third hour - Administer 90 percent (450 mL)
Carboplatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <description>Anaphylaxis is considered a serious adverse event (or very severe hypersensitivity reaction)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity Reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Aleena Banerji</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177263850</phone>
      <email>abanerji@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

